Cytochrome P450 Enzyme Inhibition and Herb-Drug Interaction Potential of Medicinal Plant Extracts Used for Management of Diabetes in Nigeria.
Chromatography, Liquid
Cytochrome P-450 Enzyme Inhibitors
/ administration & dosage
Diabetes Mellitus
/ drug therapy
Female
Herb-Drug Interactions
Humans
Hypoglycemic Agents
/ administration & dosage
In Vitro Techniques
Inhibitory Concentration 50
Male
Microsomes, Liver
/ metabolism
Nigeria
Plant Extracts
/ administration & dosage
Plants, Medicinal
/ chemistry
Tandem Mass Spectrometry
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
pubmed:
13
4
2021
medline:
12
11
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
The use of herbal medicines is common in Africa, and patients often use a combination of herbs and drugs. Concurrent herbal and pharmaceuticals treatments can cause adverse effects through herb-drug interactions (HDI). This study evaluated the potential risk of HDI for five medicinal plants, Vernonia amygdalina, Ocimum gratissimum, Moringa oleifera, Azadirachta indica, and Picralima nitida, using in vitro assays. Patients with diabetes and some other disease conditions commonly use these medicinal plants in Nigeria, and little is known regarding their potential for drug interaction, despite their enormous use. Crude extracts of the medicinal plants were evaluated for reversible and time-dependent inhibition (TDI) activity of six cytochrome P450 (CYP) enzymes using pooled human liver microsomes and cocktail probe-based assays. Enzyme activity was determined by quantifying marker metabolites' formation using liquid chromatography-mass spectrometry/mass spectrometry. The drug interaction potential was predicted for each herbal extract using the in vitro half-maximal inhibitory concentration (IC O. gratissimum methanol extracts reversibly inhibited CYP 1A2, 2C8, 2C9 and 2C19 enzymes (IC The medicinal plants inhibited CYP activity in vitro, with the potential to cause in vivo HDI. Clinical risk assessment and proactive monitoring are recommended for patients who use these medicinal plants concurrently with drugs that are cleared through CYP metabolism.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
The use of herbal medicines is common in Africa, and patients often use a combination of herbs and drugs. Concurrent herbal and pharmaceuticals treatments can cause adverse effects through herb-drug interactions (HDI). This study evaluated the potential risk of HDI for five medicinal plants, Vernonia amygdalina, Ocimum gratissimum, Moringa oleifera, Azadirachta indica, and Picralima nitida, using in vitro assays. Patients with diabetes and some other disease conditions commonly use these medicinal plants in Nigeria, and little is known regarding their potential for drug interaction, despite their enormous use.
METHODS
METHODS
Crude extracts of the medicinal plants were evaluated for reversible and time-dependent inhibition (TDI) activity of six cytochrome P450 (CYP) enzymes using pooled human liver microsomes and cocktail probe-based assays. Enzyme activity was determined by quantifying marker metabolites' formation using liquid chromatography-mass spectrometry/mass spectrometry. The drug interaction potential was predicted for each herbal extract using the in vitro half-maximal inhibitory concentration (IC
RESULTS
RESULTS
O. gratissimum methanol extracts reversibly inhibited CYP 1A2, 2C8, 2C9 and 2C19 enzymes (IC
CONCLUSIONS
CONCLUSIONS
The medicinal plants inhibited CYP activity in vitro, with the potential to cause in vivo HDI. Clinical risk assessment and proactive monitoring are recommended for patients who use these medicinal plants concurrently with drugs that are cleared through CYP metabolism.
Identifiants
pubmed: 33844145
doi: 10.1007/s13318-021-00685-1
pii: 10.1007/s13318-021-00685-1
doi:
Substances chimiques
Cytochrome P-450 Enzyme Inhibitors
0
Hypoglycemic Agents
0
Plant Extracts
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437-450Subventions
Organisme : NIH HHS
ID : P42ES027706
Pays : United States
Références
Ogbera A, Dada O, Adeleye F, Jewo P. Complementary and alternative medicine use in diabetes mellitus. West Afr J Med. 2011;29(3):58–62.
Ezeome ER, Anarado AN. Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. BMC Complement Altern Med. 2007. https://doi.org/10.1186/1472-6882-7-28 .
doi: 10.1186/1472-6882-7-28
pubmed: 17850665
pmcid: 2034592
Ilomuanya MO, Okubanjo OO, Azubuike C, Oguntibeju A, Ajiboye D, Maduka C. Evaluation of the frequency of use of herbal drugs with concomitant administration of highly active antiretroviral therapy and its effect on medication adherence in two health care facilities in southwestern Nigeria. J AIDS HIV Res. 2017;9(1):8–16.
doi: 10.5897/JAHR2016.0399
Amaeze OU, Aderemi-Williams RI, Ayo-Vaughan MA, Ogundemuren DA, Ogunmola DS, Anyika EN. Herbal medicine use among Type 2 diabetes mellitus patients in Nigeria: understanding the magnitude and predictors of use. Int J Clin Pharm. 2018;40(3):580–8.
pubmed: 29721742
doi: 10.1007/s11096-018-0648-2
pmcid: 29721742
Chang HYA, Wallis M, Tiralongo E. Use of complementary and alternative medicine among people with type 2 diabetes in Taiwan: a cross-sectional survey. Evid Based Complement Altern Med. 2011. https://doi.org/10.1155/2011/983792 .
doi: 10.1155/2011/983792
Mwangi J, Gitonga L. Perceptions and use of herbal remedies among patients with diabetes mellitus in Murang’a North District, Kenya. Open J Clin Diagn. 2014;4:152–72.
doi: 10.4236/ojcd.2014.43024
Singh J, Gautam C, Singh R. Self-medication with herbal remedies amongst patients of type 2 diabetes mellitus: a preliminary study. Indian J Endocrinol Metab. 2012;16(4):662–3.
pubmed: 22837942
pmcid: 3401782
doi: 10.4103/2230-8210.98041
Jou J, Johnson PJ. Nondisclosure of complementary and alternative medicine use to primary care physicians: findings from the 2012 national health interview survey. JAMA Intern Med. 2016;176(4):545–6.
pubmed: 26999670
doi: 10.1001/jamainternmed.2015.8593
pmcid: 26999670
Ben-Arye E, Attias S, Levy I, Goldstein L, Schiff E. Mind the gap: disclosure of dietary supplement use to hospital and family physicians. Patient Educ Couns. 2017;100(1):98–103.
pubmed: 27516439
doi: 10.1016/j.pec.2016.07.037
pmcid: 27516439
Gerber W, Steyn JD, Kotzé AF, Hamman JH. Beneficial pharmacokinetic drug interactions: a tool to improve the bioavailability of poorly permeable drugs. Pharmaceutics. 2018;10(3):106.
pmcid: 6161083
doi: 10.3390/pharmaceutics10030106
Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herb-drug interaction studies with special focus on interplays. Porto Biomed J. 2019;4(2):e15.
pubmed: 31595257
pmcid: 6726296
doi: 10.1016/j.pbj.0000000000000015
Kalgutkar AS, Obach AR, Maurer TS. Mechanism-based inactivation of Cytochrome P450 enzymes chemical mechanisms, structure-activity relationships, and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab. 2007;8(5):407–47.
pubmed: 17584015
doi: 10.2174/138920007780866807
pmcid: 17584015
Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KHJ, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab Dispos. 2009;37(7):1355–70.
pubmed: 19359406
doi: 10.1124/dmd.109.026716
pmcid: 19359406
Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol. 2005;29(7):755–8.
pubmed: 16419414
doi: 10.1093/jat/29.7.755
pmcid: 16419414
Mamindla S, Kvsrg P, Koganti B. Herb-drug interactions: an overview of mechanisms and clinical aspects. Int J Pharm Sci Res. 2016;7(9):3576–86.
Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Mol Nutr Food Res. 2008;52(7):755–63.
pubmed: 18214849
pmcid: 2562884
doi: 10.1002/mnfr.200600300
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415–26.
pubmed: 15900287
pmcid: 1894911
doi: 10.1016/j.clpt.2005.01.009
Showande JS, Fakeye TO, Tolonen A, Hokkanen J. In vitro inhibitory activities of the extract of Hibiscus sabdariffa L. (family Malvaceae) on selected cytochrome P450 isoforms. Afr J Tradit Complement Altern Med AJTCAM. 2013;10(3):533–40.
Gbolade AA. Inventory of antidiabetic plants in selected districts of Lagos State, Nigeria. J Ethnopharmacol. 2009;121(1):135–9.
pubmed: 19013225
doi: 10.1016/j.jep.2008.10.013
pmcid: 19013225
Borokini TI, Ighere DA, Clement M, Ajiboye TO, Alowonle AA. Ethnobiological survey of traditional medicine practice for the treatment of piles and diabetes mellitus in Oyo State. J Med Plant Stud. 2013;1:30–40.
Ezuruike U, Prieto JM. Assessment of potential herb-drug interactions among Nigerian adults with type-2 diabetes. Front Pharmacol. 2016;10(7):248.
Al-awar MSA, Muaqeb AAA, Salih EMA. Antihyperglycemic and hypolipidemic effect of Azadirachta indica leaves aqueous extract in alloxan-induced diabetic male rabbits. Int J Pharm Biol Arch. 2018;9(1):47–51.
Ejike CECC, Awazie SO, Nwangozi PA, Godwin CD. Synergistic postprandial blood glucose modulatory properties of Vernonia amygdalina (Del.), Gongronema latifolium (Benth.) and Ocimum gratissimum (Linn.) aqueous decoctions. J Ethnopharmacol. 2013;149(1):111–6.
pubmed: 23770031
doi: 10.1016/j.jep.2013.06.009
pmcid: 23770031
Khan W, Parveen R, Chester K, Parveen S, Ahmad A. Hypoglycemic potential of aqueous extract of Moringa oleifera leaf and in vivo GC-MS metabolomics. Front Pharmacol. 2017;12(8):577.
doi: 10.3389/fphar.2017.00577
Okon U, Owo D, Udokang N, Udobang J, Ekpenyong C. Oral administration of aqueous leaf extract of Ocimum gratissimum ameliorates polyphagia, polydipsia and weight loss in streptozotocin-induced diabetic rats. Am J Med Med Sci. 2012;2(3):45–9.
doi: 10.5923/j.ajmms.20120203.04
Okonta JM, Aguwa CN. Evaluation of the hypoglycemic activity of glycosides and alkaloids extracts of Picralima nitida stapf (Apocynaceae) seed. Int J Pharmacol. 2007;3(6):505–9.
doi: 10.3923/ijp.2007.505.509
Zenebe MM, Dessie BK, Wana GG, Werkneh AA. Isolation, structural elucidation, and bioactivity studies of leaf extract of Vernonia amygdalina. Am J Appl Chem. 2015;3(1):14–20.
doi: 10.11648/j.ajac.20150301.13
Akinmoladun AC, Ibukun EO, Afor E, Obuotor EM, Farombi EO. Phytochemical constituent and antioxidant activity of extract from the leaves of Ocimum gratissimum. Sci Res Essays. 2007;2(5):163–6.
Konmy BB, Olounladé PA, Allou SD, Azando EVB, Hounzangbé-Adoté MS, Olounladé CPA. A review on phytochemistry and pharmacology of Moringa oleifera leaves (Moringaceae). J Pharmacogn Phytochem. 2016;5(5):325–30.
Erharuyi O, Falodun A, Langer P. Medicinal uses, phytochemistry and pharmacology of Picralima nitida (Apocynaceae) in tropical diseases: a review. Asian Pac J Trop Med. 2014;7:1–8.
pubmed: 24418074
doi: 10.1016/S1995-7645(13)60182-0
pmcid: 24418074
Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. Biological activities and medicinal properties of neem (Azadirachta indica). Curr Sci. 2002;82(11):1336–45.
Orellana-Paucar A, Vintimilla-Rojas D. Interactions of clinical relevance associated with concurrent administration of prescription drug and food or medicinal plants: a systematic review protocol. Systems Control Found Appl. 2020. https://doi.org/10.1186/s13643-019-1259-2 .
doi: 10.1186/s13643-019-1259-2
Ameade EPK, Ibrahim M, Ibrahim H-S, Habib RH, Gbedema SY. Concurrent use of herbal and orthodox medicines among residents of Tamale, Northern Ghana, who patronize hospitals and herbal clinics. Evid Based Complement Altern Med. 2018. https://doi.org/10.1155/2018/1289125 .
doi: 10.1155/2018/1289125
Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. Diabetol Metab Syndr. 2017;9(1):1–12.
doi: 10.1186/s13098-017-0254-9
Aluefua OF, Chika A, Muhammad AA, Usman A. Interactions between herbs and antidiabetic drugs: a systematic review. Res J Pharmacol. 2017;11(5):6–17.
Zimmerlin A, Trunzer M, Faller B. CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos. 2011;39(6):1039–46.
pubmed: 21383203
doi: 10.1124/dmd.110.037911
pmcid: 21383203
Yates P, Eng H, Di L, Obach RS. Statistical methods for analysis of time-dependent inhibition of cytochrome P450 enzymes. Drug Metab Dispos. 2012;40(12):2289–96.
pubmed: 22942318
doi: 10.1124/dmd.112.047233
pmcid: 22942318
Showande SJ, Fakeye TO, Kajula M, Hokkanen J, Tolonen A. Potential inhibition of major human cytochrome P450 isoenzymes by selected tropical medicinal herbs—implication for herb–drug interactions. Food Sci Nutr. 2019. https://doi.org/10.1002/fsn3.789 .
doi: 10.1002/fsn3.789
pubmed: 30680158
pmcid: 30680158
Awortwe C, Bouic P, Masimirembwa C, Rosenkranz B. Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa–implications for herb-drug interactions. Drug Metab Lett. 2014;7(2):83–95.
pubmed: 24475926
pmcid: 4354708
doi: 10.2174/1872312808666140129123210
Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos. 2014;42(3):301–17.
pubmed: 24335390
pmcid: 3935140
doi: 10.1124/dmd.113.055236
Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008;9(5):625–37.
pubmed: 18466106
doi: 10.2217/14622416.9.5.625
pmcid: 18466106
Thelingwani RS, Dhansay K, Smith P, Chibale K, Masimirembwa CM. Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa. Xenobiotica. 2012;42(10):989–1000.
pubmed: 22533317
doi: 10.3109/00498254.2012.681077
pmcid: 22533317
Fasinu PS, Gutmann H, Schiller H, James AD, Bouic PJ, Rosenkranz B. The potential of sutherlandia frutescens for herb-drug interaction. Drug Metab Dispos. 2013;41(2):488–97.
pubmed: 23209194
doi: 10.1124/dmd.112.049593
pmcid: 23209194
Parkinson A, Ogilvie BW, Buckley DB, Kazmi F, Czerwinski M, Parkinson O. Biotransformation of xenobiotics. In: Casarett and Soull's toxicology, the basic science of poisons. 8th ed McGraw-Hill Education; 2013. p. 186–363.
Thomford NE, Dzobo K, Chopera D, Wonkam A, Maroyi A, Blackhurst D, et al. In vitro reversible and time-dependent CYP450 inhibition profiles of medicinal herbal plant extracts Newbouldia laevis and Cassia abbreviata: Implications for herb-drug interactions. Molecules. 2016;21(2):211.
pmcid: 6273559
doi: 10.3390/molecules21020211
Yi JM, Kim YA, Lee YJ, Bang OS, Kim NS. Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro. BMC Complement Altern Med. 2015. https://doi.org/10.1186/s12906-015-0965-0 .
doi: 10.1186/s12906-015-0965-0
pubmed: 26683337
pmcid: 4683934
Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol. 2011;82:681–91.
pubmed: 21726541
pmcid: 3159548
doi: 10.1016/j.bcp.2011.06.027
Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and clinical considerations. J Personal Med. 2018;8(1):1.
doi: 10.3390/jpm8010001
Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JHM, Meijerman I. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J Ethnopharmacol. 2013;149(2):543–9.
pubmed: 23876595
doi: 10.1016/j.jep.2013.07.014
pmcid: 23876595
Chiangsom A, Lawanprasert S, Oda S, Kulthong K, Luechapudiporn R, Yokoi T, et al. Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. Drug Metab Pharmacokinet. 2016;31(3):210–7.
pubmed: 27212065
doi: 10.1016/j.dmpk.2016.04.002
pmcid: 27212065
Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven LJ. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69–76.
pubmed: 27388693
doi: 10.1038/gim.2016.80
pmcid: 27388693
Gopisankar MG. CYP2D6 pharmacogenomics. Egypt J Med Hum Genet. 2017;18(4):309–13.
doi: 10.1016/j.ejmhg.2017.03.001
Monera TG, Wolfe AR, Maponga CC, Benet LZ, Guglielmo J. Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. J Infect Dev Ctries. 2008;2(5):379–83.
pubmed: 19745507
pmcid: 5385924
doi: 10.3855/jidc.201
Awortwe C, Manda V, Avonto C, Khan S, Khan I, Walker L, et al. In vitro evaluation of reversible and time-dependent inhibitory effects of Kalanchoe crenata on CYP2C19 and CYP3A4 Activities. Drug Metab Lett. 2015;9:48–62.
pubmed: 25600201
pmcid: 5656046
doi: 10.2174/1872312809666150119110200
Taesotikul T, Navinpipatana V, Tassaneeyakul W. Selective inhibition of human cytochrome P450 1A2 by Moringa oleifera. J Pharmacol. 2010;32(1):256–8.
Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.
pubmed: 18043468
doi: 10.1097/FTD.0b013e31815c16f5
pmcid: 18043468
VandenBrink BM, Isoherranen N. The role of metabolites in predicting drug-drug interactions: Focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Dev. 2010;13(1):66–77.
Mustapíc DŠ, Debeljak Ž, Maleš Ž, Bojíc M. The inhibitory effect of flavonoid aglycones on the metabolic activity of CYP3A4 enzyme. Molecules. 2018;23(10):2553.
doi: 10.3390/molecules23102553
Atkinson A, Kenny JR, Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos. 2005;23(10):2553.
Riley RJ, Wilson CE. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. Expert Opin Drug Metab Toxicol. 2015;11(4):557–72.
pubmed: 25659570
doi: 10.1517/17425255.2015.1013095
pmcid: 25659570
Thomford NE, Dzobo K, Chopera D, Wonkam A, Skelton M, Blackhurst D, et al. Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition. Pharmaceuticals. 2015;8(3):637–63.
pubmed: 26402689
pmcid: 4588186
doi: 10.3390/ph8030637
Wong SG, Lee M, Wong BK. Single concentration loss of activity assay provides an improved assessment of drug–drug interaction risk compared to IC50-shift. Xenobiotica. 2016;46(11):953–66.
pubmed: 26956546
doi: 10.3109/00498254.2016.1143139
pmcid: 26956546
Kosaka M, Kosugi Y, Hirabayashi H. Risk assessment using cytochrome P450 time-dependent inhibition assays at single time and concentration in the early stage of drug discovery. J Pharm Sci. 2017;106(9):2838–46.
doi: 10.1016/j.xphs.2017.04.077